CN103446500B - Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction - Google Patents
Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction Download PDFInfo
- Publication number
- CN103446500B CN103446500B CN201310420009.3A CN201310420009A CN103446500B CN 103446500 B CN103446500 B CN 103446500B CN 201310420009 A CN201310420009 A CN 201310420009A CN 103446500 B CN103446500 B CN 103446500B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- cyclomastopathy
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 85
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 235000013336 milk Nutrition 0.000 title abstract description 13
- 210000004080 milk Anatomy 0.000 title abstract description 13
- 239000008267 milk Substances 0.000 title abstract description 13
- 208000002193 Pain Diseases 0.000 title abstract description 11
- 230000036407 pain Effects 0.000 title abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 241000628997 Flos Species 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 21
- 206010006298 Breast pain Diseases 0.000 claims description 18
- 208000006662 Mastodynia Diseases 0.000 claims description 18
- 206010060710 Galactostasis Diseases 0.000 claims description 17
- 239000002552 dosage form Substances 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 238000007796 conventional method Methods 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 38
- 210000003734 kidney Anatomy 0.000 abstract description 20
- 210000004185 liver Anatomy 0.000 abstract description 18
- 230000001105 regulatory effect Effects 0.000 abstract description 16
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 206010003549 asthenia Diseases 0.000 abstract description 3
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 abstract 1
- 235000008326 Trichosanthes anguina Nutrition 0.000 abstract 1
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- 241000700159 Rattus Species 0.000 description 27
- 238000000605 extraction Methods 0.000 description 22
- 210000000481 breast Anatomy 0.000 description 20
- 210000005075 mammary gland Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 206010020718 hyperplasia Diseases 0.000 description 12
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 208000019395 Lactation disease Diseases 0.000 description 7
- 206010042576 Suppressed lactation Diseases 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108050006400 Cyclin Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000037006 agalactosis Effects 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 239000003163 gonadal steroid hormone Substances 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 238000004064 recycling Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000027758 ovulation cycle Effects 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 102000015694 estrogen receptors Human genes 0.000 description 4
- 108010038795 estrogen receptors Proteins 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 102000003998 progesterone receptors Human genes 0.000 description 4
- 108090000468 progesterone receptors Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000003390 Chinese drug Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 210000002149 gonad Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229950002007 estradiol benzoate Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000283956 Manis Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 206010065347 Premenstrual pain Diseases 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 108010037528 lactotropin Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000010070 molecular adhesion Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000008971 rukuaixiao Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- AEQDJSLRWYMAQI-KRWDZBQOSA-N tetrahydropalmatine Chemical group C1CN2CC(C(=C(OC)C=C3)OC)=C3C[C@H]2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-KRWDZBQOSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction. The traditional Chinese medicine composition provided by the invention has the effects of tonifying kidney, soothing the liver, regulating the chong and ren meridians, invigorating blood circulation and removing stasis and is used for treating diseases such as the kidney-asthenia and liver depression type cyclomastopathy, the mammary pain and the postpartum milk obstruction. The traditional Chinese medicine composition is mainly prepared from the following medicinal raw materials in parts by weight: 9-15 parts of cornu cervi degelatinatum, 9-15 parts of cassia twig, 9-15 parts of radix bupleuri, 8-12 parts of snakegourd fruit, 8-12 parts of angelica, 8-12 parts of ligusticum wallichii, 5-9 parts of fructus liquidambaris, 9-15 parts of raw oyster shell, 5-9 parts of flos albiziae and 5-9 parts of raw malt.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, be particularly used for the treatment of cyclomastopathy, mastalgia and puerperal galactostasis Chinese medicine composition, relate to preparation method and the application of said composition simultaneously.
Background technology
Cyclomastopathy occupies first of cystic hyperplasia of breast morbidity, the women of 70% ~ 80% is about had to have cyclomastopathy in various degree according to investigations, developed country about 1/3 women suffers from this disease, and data confirms that primary disease is a kind of precancerous lesion, and its chance suffered from breast cancer is 3 ~ 5 times of general female.Its sickness rate is in ascendant trend year by year in recent years, and age of onset becomes younger gradually.
Cyclomastopathy is the modal cystic hyperplasia of breast of women, and its sickness rate accounts for the first place of mastopathy.Cyclomastopathy is mammary gland tissue conduit and lobule degeneration structurally and the growth of Progressive symmetric erythrokeratodermia connective tissue, can betide the women at postpubertal any age, common with the young women of 18 ~ 50 years old.Majority shows as breast lamellar and nodular hyperplasia enclosed mass clinically, or presents migrans distending pain, touches a tender spot, and premenstrual pain aggravates.Along with the development of social modernization's process, the update of electronic product, the cultural life of people also becomes and becomes increasingly abundant and anxiety, the sickness rate of mastalgia constantly raises, breast is the vitals of women, hypertrophy and pain annoying numerous women, current physician thinks relevant with endocrine disturbance and Nervous and Mental Factors, but because the cause of disease of cyclomastopathy and mastalgia thereof is still not very clear, most of patients is difficult to the treatment accepting doctor trained in Western medicine analgesic, and Chinese medicine market lacks this type of medicine, this is a difficult problem urgently to be resolved hurrily.
In addition, clinically early and effective treatment cyclomastopathy, the generation for Breast Cancer Prevention is significant.For many years, western medical treatment cyclomastopathy commonly uses androgens and other symptomatic treatment medicines.But there is certain side effect in the treatment of application androgen, if any some manlike performances, infringement liver etc.It is little that Chinese traditional treatment cyclomastopathy has toxic and side effects, the advantages such as expense is low, be the Main Means of domestic current treatment primary disease, it has feasibility delaying, block and reverse cyclomastopathy in breast cancer development, but existing Chinese medicine preparation curative effect is not very good.In addition, more than 60% is had to have mastalgia in cyclomastopathy, because doctor trained in Western medicine analgesic is to side effect such as the infringements of gastrointestinal tract and liver, make most of patients refuse the treatment of Western medicine, and Chinese medicine market lack the medicine that this type of fundamentally can treat mastalgia.
Hypogalactia, agalactia, galactostasis are also puerpera's commonly encountered diseases, one of frequently-occurring disease, and according to the statistics of World Health Organization, there is 47.6% puerpera's agalactia or hypogalactia in the whole world, and its popularity certainly will affect the growth promoter of baby, also causes extreme difficulties to suckling.As everyone knows, breast feeding is all helpful to mother and baby, wherein breast milk, especially the endocrine colostrum of 5d in puerperal to the growth promoter of baby, to resist disease significant.Colostrum also has the effect promoting lipid excretion, reduces the generation of jaundice.Meanwhile, suckling is also conducive to mother's health, and sucking milk by baby can stimulate mother's uterine contraction, reduces postpartum hemorrhage, also can reduce the morbidity of breast carcinoma and cervical cancer.Therefore, the patient of puerperal hypogalactia is treated timely and effectively, especially promote the increase of breast milk secretion in initial several days of puerperal, improve hypogalactia, agalactia, galactostasis, meet the needs that baby feeds nursing, have very important meaning.
Basic Theories of Chinese Medicine thinks that breast belongs to stomach, and nipple belongs to liver, puerperal milk very less or agalactia be called " hypogalactia ", also known as hypogalactia, because of stagnation of QI due to depression of the liver, milk run be obstructed caused by.Because of childbirth severe loss of blood, or ferritic is weak, deficiency of kidney-QI, the traditional Chinese medical science thinks the angry blood of essence and bloodization, and be above milk, lower is menses, consume impairment of QI blood puerperal, thus deficiency of vital energy insufficiency of blood, milk thus very less or completely without, in addition puerperal easy depressed emotion, irritability stasis, hinder caused by milk runs, should the kidney invigorating soothing liver-QI, QI invigorating nourishing the stomach, blood circulation promoting and blood stasis dispelling, dredging collateral for promoting lactation controls it.TCM Document is a lot of about the experience prescription of hypogalactia, agalactia, many employings are traditional in the past decoction, pill etc., and preparation is simple, and dosage is forbidden, and taste is uncomfortable, and mouthfeel is poor, swallows to carry inconvenience, is unfavorable for packed and transported and storage, easy moldy metamorphism.
But, can find from above-mentioned summary, the treatment cyclomastopathy provided at present, mastalgia, puerperal galactostasis Chinese traditional patent formulation be all treat for specific typing, after needing doctor to diagnose in Clinical practice, the state of an illness according to concrete patient carries out corresponding selection and adjustment, thus forms specific prescription.This and patient are desirably in pharmacy oneself and select the expectation of medicine not conform to according to symptom.At present, in Chinese traditional patent formulation, also its three diseases are not all had to the formula of special efficacy.
Chinese patent literature CN1509743A discloses a stimulating milk secretion oral liquid, adopt Radix Bupleuri, Fructus Gardeniae, Pericarpium Citri Reticulatae, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Rhizoma Chuanxiong, Fructus Hordei Germinatus, Radix Rhapontici, Fructus Liquidambaris, Squama Manis, Wang Buliu, Radix Glycyrrhizae formulated, this prescription biases toward liver-smoothing, qi-regulating, promoting blood circulation to remove obstruction in the collateral, is only applicable to the cyclomastopathy caused by stagnation of QI due to depression of the liver blood stasis.
Chinese patent literature CN1857512A disclose a kind of treat puerperal breast less, the Chinese medicine of agalactia, galactostasis, by the Radix Paeoniae Alba of the Chinese crude drug Radix Astragali, Radix Rehmanniae Preparata, Medulla Tetrapanacis, Herba Dianthi, Radix Trichosanthis, Fructus Liquidambaris, Radix Rhapontici, Radix Codonopsis, Radix Angelicae Sinensis, Rhizoma Chuanxiong, wine parch, Semen Vaccariae, Radix Bupleuri, scald river Squama Manis, Cornu Cervi Degelatinatum ten five kinds of Chinese medicine of system, appropriate amount of auxiliary materials mixed preparing forms, and it is characterized in that this medicine is hard capsule or tablet.The kidney-reinforcing drug such as the medicine Radix Astragali, Radix Rehmanniae Preparata, Radix Codonopsis, Cornu Cervi of the existing the kidney invigorating of this prescription, also has the product Radix Angelicae Sinensis of the soothing liver-QI that nourishes blood, Rhizoma Chuanxiong, the Radix Paeoniae Alba, Radix Bupleuri.But breast belongs to stomach, nipple belongs to liver, and clinical milk reduces, obstructed, and how to digest relevant with taste, do not solve transporting and transforming function of the spleen and stomach problem, QI and blood is still without the source of vital function, what takes milk? said medicine can not effectively solve the problem, and clinical efficacy is not good.
Chinese patent literature CN101716299A discloses a kind of Chinese medicine composition for the treatment of cyclomastopathy, is made up of the crude drug of following weight: Concha Ostreae 30 grams, Thallus Laminariae (Thallus Eckloniae) 15 grams, Radix Bupleuri 15 grams, the Radix Astragali 15 grams, Radix Angelicae Sinensis 15 grams, Radix Salviae Miltiorrhizae 15 grams, Radix Paeoniae Rubra 15 grams, the Rhizoma Atractylodis Macrocephalae 15 grams, 10 grams, Poria, Semen Fructus Trichosanthis 10 grams, Rhizoma Chuanxiong 10 grams, Radix Asparagi 10 grams, Rhizoma Sparganii 10 grams, 10 grams, Pericarpium Citri Reticulatae Viride, Semen Citri Reticulatae 10 grams, but above-mentioned prescription drug is complicated, clinical practice shows, the party is only for particular patient, not good enough to most of patients curative effect.
Chinese medicine prevent and treat cystic hyperplasia of breast, mastalgia, puerperal the disease such as galactostasis there is unique advantage, but due to such disease pathogenesis indefinite, on market most Chinese patent medicine based on simple the kidney invigorating, send an expedition against, regulate the flow of vital energy, eliminating stagnation, late result is not good enough.
Summary of the invention
In order to solve the various problems existed in prior art, we sum up the pathogenic characteristic of cyclomastopathy for " suffer from a deficiency of the kidney, Chong and Ren channel disorder is this; the stagnation of QI, expectorant are solidifying, blood stasis is mark " by Study of Etiology, establish the kidney invigorating soothing liver-QI, the therapeutic rules of regulating qi-flowing for harmonizing stomach, hard masses softening and resolving, in conjunction with theoretical and modern pharmacological research achievement at all times, obtain Chinese medicine composition of the present invention, it melts adjusts benefits, stomach function regulating, is melt into one, for treat cyclomastopathy, mastalgia, puerperal the curative effect of disease such as galactostasis remarkable.
An object of the present invention, provide a kind of effective treatment cyclomastopathy, mastalgia, puerperal galactostasis and/or the method for relevant disease.
An object of the present invention, provide a kind of treat cyclomastopathy, mastalgia, puerperal galactostasis Chinese medicine composition.
An object of the present invention, provides a kind of method preparing described Chinese medicine composition.
An object of the present invention, provide a kind of described Chinese medicine composition prepare cyclomastopathy, mastalgia, puerperal galactostasis medicine in application.
Chinese medicine composition of the present invention is made primarily of following crude drug, based on parts by weight, and Cornu Cervi Degelatinatum 9-15 part, Ramulus Cinnamomi 9-15 part, Radix Bupleuri 9-15 part, Fructus Trichosanthis 8-12 part, Radix Angelicae Sinensis 8-12 part, Rhizoma Chuanxiong 8-12 part, Fructus Liquidambaris 5-9 part, Concha Ostreae 9-15 part, Flos Albiziae 5-9 part, Fructus Hordei Germinatus 5-9 part.
As one of preferred embodiment of the present invention, Chinese medicine composition of the present invention is made, based on parts by weight primarily of following crude drug, Cornu Cervi Degelatinatum 10-13 part, Ramulus Cinnamomi 10-13 part, Radix Bupleuri 10-13 part, Fructus Trichosanthis 9-11 part, Radix Angelicae Sinensis 9-11 part, Rhizoma Chuanxiong 9-11 part, Fructus Liquidambaris 6-8 part, Concha Ostreae 10-14 part, Flos Albiziae 6-8 part, Fructus Hordei Germinatus 6-8 part.
As one of preferred embodiment of the present invention, Chinese medicine composition of the present invention is made, based on parts by weight primarily of following crude drug, Cornu Cervi Degelatinatum 12 parts, Ramulus Cinnamomi 12 parts, Radix Bupleuri 12 parts, Fructus Trichosanthis 10 parts, Radix Angelicae Sinensis 10 parts, Rhizoma Chuanxiong 10 parts, Fructus Liquidambaris 7 parts, Concha Ostreae 12 parts, Flos Albiziae 7 parts, Fructus Hordei Germinatus 7 parts.
As one of preferred embodiment of the present invention, Chinese medicine composition of the present invention is made primarily of following crude drug, based on parts by weight, and Cornu Cervi Degelatinatum 12g, Ramulus Cinnamomi 12g, Radix Bupleuri 10g, Fructus Trichosanthis 12g, Radix Angelicae Sinensis 9g, Rhizoma Chuanxiong 9g, Fructus Liquidambaris 7g, Concha Ostreae 12g, Flos Albiziae 7g, Fructus Hordei Germinatus 6g.
The present invention with Cornu Cervi Degelatinatum, Ramulus Cinnamomi, Radix Bupleuri for monarch drug, warming and recuperating the kidney-YANG, promoting the circulation of blood subside a swelling, liver-smoothing, qi-regulating, kidney tonifying lactogenesis, be aided with Fructus Trichosanthis, Fructus Liquidambaris, Concha Ostreae reduce phlegm, hard masses softening and resolving is minister, assistant is with Radix Angelicae Sinensis, Rhizoma Chuanxiong, Flos Albiziae vital energy regualting and blood circulation-promoting, make with Fructus Hordei Germinatus dredging collateral for promoting lactation, the kidney invigorating soothing liver-QI is played, the effect of regulating qi-flowing for harmonizing stomach, hard masses softening and resolving altogether by full side, melt and adjust benefits, stomach function regulating, be melt into integrally, for cyclomastopathy, mastalgia, puerperal the disease such as galactostasis.
Monarch drug: Cornu Cervi Degelatinatum has effect of the kidney warming sun, bone and muscle strengthening, promoting the circulation of blood detumescence.There is antiinflammatory, analgesic activity, have and suppress the effect of cyclomastopathy, can the growth of Tumor suppression, promote anti-tumor immune response, activate immunity mechanism, killing tumor cell, is conducive to oncotherapy.Ramulus Cinnamomi has promoting the flow of QI-blood by warming the meridian, and effect of the positive pain of dehumidifying, all has obvious anti-pain effect to mice thermic pain and acetic acid induced pain, and analgesic effect and the rotundine group of the appearance of Ramulus Cinnamomi alcohol extract are close.Radix Bupleuri has soothing liver-QI for relieving depression, effect of elevate a turnable ladder yang-energy, and modern pharmacology research proves that Radix Bupleuri has the effects such as antiinflammatory, analgesia, antitumor, immunomodulating.Saikoside has antitumor cell molecular adhesion, and interference tumor cell s phase DNA synthesizes and protein metabolism, antiproliferative effect, the effect of cell death inducing.Radix Bupleuri has immunoregulation effect.
Ministerial drug: Fructus Trichosanthis has clearing away heat and eliminating phlegm, relieving stuffiness of the chest by dispersing aggregation of pathogens, moisturizes effect of laxation.Pharmacological research confirms, Fructus Trichosanthis has anti-inflammatory and antalgic, improves the multiple pharmacological effect such as autoimmune ability, Tumor suppression growth.Research finds, effect that Fructus Liquidambaris has dispelling, collateral-activating, diuretic stimulates the menstrual flow.Modern pharmacological research display Fructus Liquidambaris has antiinflammatory, analgesic activity, the acid of road road has certain anti-inflammatory activity for its known principle active component, the mice foot swelling that can obviously suppress carrageenin to cause, Dichlorodiphenyl Acetate induced mice abdominal cavity capillary permeability is hyperfunction demonstrates certain inhibitory action, and Dichlorodiphenyl Acetate causes mice pain to have certain analgesic activity.Concha Ostreae has effect of suppressing the hyperactive liver and subsiding YANG, hard masses softening and resolving.The effect such as Concha Ostreae has enhancing immunity, antitumor, slow down aging, protect the liver.Experimentation display oyster active peptides can the propagation of inhibition tumor cell, promotes apoptosis, and its mechanism may with apoptosis-induced gene expression to be in harmonious proportion Cycle Arrest relevant.
Adjuvant drug: effect of Radix Angelicae Sinensis is invigorated blood circulation for enriching blood, menstruction regulating and pain relieving, loosening bowel to relieve constipation, there is antiinflammatory, strengthen the effect such as immunization, antitumor, inhibited to the strain of kinds of tumors tumor, can obviously grow by Tumor suppression, increase macrophage numbers, strengthen its phagocytic function and splenocyte NK activity, obviously extend the animal survival phase.Rhizoma Chuanxiong has effect of blood-activating and qi-promoting wind-expelling pain-stopping.There is analgesia, the effect such as anticancer.Research shows, Rhizoma Chuanxiong has direct antitumor action, simultaneously the adhesive attraction of ligustrazine inhibition tumor cell and endotheliocyte, and the effect of anticoagulation and antiplatelet aggregation, decreases the transfer of tumor.The regulator solution of ligustrazine to immunocyte serves the effect of killing off tumor cells.Flos Albiziae has QI regulating by alleviation of mental depression, active effect of calming the nerves, there is the activity that body is widely interior, extracorporeal suppression tumor cell is bred, its main component Quercitroside has antidepressant effect, there is the effects such as antiinflammatory, antioxidation, tranquilizing soporific, immunity moderation system, significantly can suppress the activity of monoamine oxidase A, monoamine oxidase A too much accumulation in nervous tissue can produce excessive amine metabolite, causes the generation of all kinds of spirit depressing disease.
Make medicine: Fructus Hordei Germinatus has the effect of circulation of qi promoting removing food stagnancy, invigorating the spleen and regulating the stomach, stimulating milk secretion relieving distension.Modern pharmacology research shows, the Ergota compounds contained in Fructus Hordei Germinatus has the effect intending dopamine agonist sample.Dopamine, by acting on hypothalamus, makes prolactin releasing factor discharge and increases, suppress the secretion of prolactin antagonist, suppress the generation of cyclomastopathy to a certain extent.
Therefore, Chinese medicine composition of the present invention, has the kidney invigorating soothing the liver, Chong and Ren Meridians regulating, blood circulation promoting and dispersing pathogen accumulation.For liver energy stagnation type cyclomastopathy of suffering from a deficiency of the kidney, mastalgia, puerperal the disease such as galactostasis.
As one of specific embodiment of the invention scheme, Chinese medicine composition of the present invention is for the preparation of the application in treatment cyclomastopathy disease drug.
As one of specific embodiment of the invention scheme, Chinese medicine composition of the present invention is for the preparation of the application in treatment mastalgia medicine.
As one of specific embodiment of the invention scheme, Chinese medicine composition of the present invention is for the preparation of the application in treatment galactostasis medicine in puerperal.
An object of the present invention, provides a kind of method preparing described Chinese medicine composition, gets the traditional Chinese medicinal composition raw materials of the present invention by above-mentioned weight proportion, by pharmaceutics conventional method, adds customary adjuvant, is prepared into various clinical acceptable dosage form.
Further, dosage form and the exterior-applied formulation of described dosage form can be peroral dosage form also can be topical, include but not limited to the one in the middle of following dosage form: tablet, capsule, soft capsule, patch, gel, injection, pill, granule, suspensoid, drop pill or oral liquid etc.
As one of specific embodiment of the invention scheme, the preparation method of Chinese medicine composition of the present invention is preferably, the part or all of crude drug of solvent extraction, concentrated, remove impurity, after drying, again according to a conventional method, add customary adjuvant, be prepared into various clinical acceptable dosage form.Described solvent be preferably water, ethanol, acetone, chloroform, ethyl acetate, methanol one or more.
As one of specific embodiment of the invention scheme, the preparation method of Chinese medicine composition of the present invention preferably includes following steps:
1. above ten raw material of Chinese medicine medicines are got by above proportioning dosage;
2. get eight taste Chinese herbal medicine except Cornu Cervi Degelatinatum and Concha Ostreae, soak, heating extraction 3 times, each 1-3 hour, merge the decocting liquid of three times;
3. Cornu Cervi Degelatinatum and Concha Ostreae are smashed to sieve to put in extraction pot and decoct separately, add water heating extraction 0.2-2 hour, retains its medicinal liquid and medicinal residues in extraction pot;
4. step decocting liquid 3. and step medicinal liquid 4. and medicinal residues are mixed in the lump and place in vacuum concentration pot, room temperature to be chilled to, adds ethanol, stir evenly, cold preservation hour, get supernatant, filter, filtrate recycling ethanol, be concentrated into the extractum that 45-60 DEG C is surveyed relative density degree 1.25-1.28.
As one of specific embodiment of the invention scheme, the preparation method of Chinese medicine composition of the present invention preferably includes following steps:
1. above ten raw material of Chinese medicine medicines are got by above proportioning dosage;
2. get eight taste Chinese herbal medicine except Cornu Cervi Degelatinatum and Concha Ostreae, add 5-10 times amount water soaking, heating extraction 3 times, each 1-3 hour, merge the decocting liquid of three times;
3. Cornu Cervi Degelatinatum and Concha Ostreae are smashed to sieve to put in extraction pot and decoct separately, add 5-10 times amount, heating extraction 0.2-2 hour, retain its medicinal liquid and medicinal residues in extraction pot;
4. step decocting liquid 3. and step medicinal liquid 4. and medicinal residues being mixed in the lump places in vacuum concentration pot, room temperature to be chilled to, adding ethanol makes alcohol content be 50-70%, stir evenly, cold preservation 10-30 hour, gets supernatant, filters, filtrate recycling ethanol, is concentrated into the extractum that 45-60 DEG C is surveyed relative density degree 1.25-1.28.
As one of specific embodiment of the invention scheme; get the dry extract of Chinese medicine composition of the present invention; add customary adjuvant; preparation process or step routinely, make clinical acceptable tablet, capsule, soft capsule, injection, pill, granule, suspensoid, drop pill or oral liquid etc.
Detailed description of the invention
Following examples further illustrate of the present invention, but never limit the scope of the present invention.Elaborate the present invention further referring to embodiment, but it will be appreciated by those skilled in the art that the present invention is not limited to the preparation method of these embodiments and use.And those skilled in the art can carry out equivalent replacement, combination, improvement to the present invention according to description of the invention or modify, but these all will comprise within the scope of the invention.
embodiment 1
Get based on weight portion, Cornu Cervi Degelatinatum 9 parts, Ramulus Cinnamomi 9 parts, Radix Bupleuri 9 parts, Fructus Trichosanthis 9 parts, Radix Angelicae Sinensis 7 parts, Rhizoma Chuanxiong 7 parts, Fructus Liquidambaris 7 parts, Concha Ostreae 12 parts, Flos Albiziae 7 parts, Fructus Hordei Germinatus 5 parts.
Cornu Cervi Degelatinatum and Concha Ostreae are smashed to sieve to put in extraction pot and are decocted separately, add 10 times of water yields, heating extraction 0.5 hour, retain its medicinal liquid and medicinal residues in extraction pot; Remaining eight medicines add 10 times of water yields and soak 1 hour, heating extraction 3 times, each 1 hour, merge the decocting liquid of three times, filter, filtrate and said extracted thing mix to be placed in vacuum concentration pot, room temperature to be chilled to, adding ethanol makes alcohol content be 55%, stirs evenly, cold preservation 30 hours, get supernatant, filter, filtrate recycling ethanol, be concentrated into the extractum that 50 DEG C are surveyed relative density degree 1.25-1.28.
Get extractum again, directly or indirectly add pharmaceutically acceptable excipient through normal process steps and make capsule.
embodiment 2
Get based on weight portion, Cornu Cervi Degelatinatum 15 parts, Ramulus Cinnamomi 15 parts, Radix Bupleuri 15 parts, Fructus Trichosanthis 12 parts, Radix Angelicae Sinensis 12 parts, Rhizoma Chuanxiong 12 parts, Fructus Liquidambaris 9 parts, Concha Ostreae 9 parts, Flos Albiziae 9 parts, Fructus Hordei Germinatus 6 parts.
Cornu Cervi Degelatinatum and Concha Ostreae are smashed to sieve to put in extraction pot and are decocted separately, add 10 times of water yields, heating extraction 0.5 hour, retain its medicinal liquid and medicinal residues in extraction pot; Remaining eight medicines add 10 times of water yields and soak 1 hour, heating extraction 3 times, each 1 hour, merge the decocting liquid of three times, filter, filtrate and said extracted thing mix to be placed in vacuum concentration pot, room temperature to be chilled to, adding ethanol makes alcohol content be 60%, stirs evenly, cold preservation 25 hours, get supernatant, filter, filtrate recycling ethanol, be concentrated into the extractum that 50 DEG C are surveyed relative density degree 1.25-1.28.
Get extractum, directly or indirectly add pharmaceutically acceptable excipient through normal process steps and make oral liquid.
embodiment 3
Get based on weight portion, Cornu Cervi Degelatinatum 12 parts, Ramulus Cinnamomi 12 parts, Radix Bupleuri 12 parts, Fructus Trichosanthis 10 parts, Radix Angelicae Sinensis 10 parts, Rhizoma Chuanxiong 10 parts, Fructus Liquidambaris 7 parts, Concha Ostreae 12 parts, Flos Albiziae 7 parts, Fructus Hordei Germinatus 7 parts.
Cornu Cervi Degelatinatum and Concha Ostreae are smashed to sieve to put in extraction pot and are decocted separately, add 10 times of water yields, heating extraction 0.5 hour, retain its medicinal liquid and medicinal residues in extraction pot; Remaining eight medicines add 10 times of water yields and soak 1 hour, heating extraction 3 times, each 1 hour, merge the decocting liquid of three times, filter, filtrate and said extracted thing mix to be placed in vacuum concentration pot, room temperature to be chilled to, adding ethanol makes alcohol content be 65%, stirs evenly, cold preservation 25 hours, get supernatant, filter, filtrate recycling ethanol, be concentrated into the extractum that 50 DEG C are surveyed relative density degree 1.25-1.28.
Get extractum, directly or indirectly add pharmaceutically acceptable excipient through normal process steps and make granule.
embodiment 4
Get based on weight portion, Cornu Cervi Degelatinatum 12 parts, Ramulus Cinnamomi 12 parts, Radix Bupleuri 10 parts, Fructus Trichosanthis 12 parts, Radix Angelicae Sinensis 9 parts, Rhizoma Chuanxiong 9 parts, Fructus Liquidambaris 7 parts, Concha Ostreae 12 parts, Flos Albiziae 7 parts, Fructus Hordei Germinatus 7 parts.
Cornu Cervi Degelatinatum and Concha Ostreae are smashed to sieve and puts in extraction pot, then add residue eight Chinese medicines, add 10 times of water yields and soak 1 hour, heating extraction 3 times, each 1 hour, merges the decocting liquid of three times, filter, room temperature to be chilled to, adds ethanol and makes alcohol content be 65%, stir evenly, cold preservation 25 hours, gets supernatant, filters, filtrate recycling ethanol, is concentrated into the extractum that 50 DEG C are surveyed relative density degree 1.25-1.28.
embodiment 5
The dry extract of the Chinese medicine composition of Example 1 gained, adds customary adjuvant, and preparation process or step, make injection routinely.
embodiment 6
The dry extract of the Chinese medicine composition of Example 2 gained, adds customary adjuvant, and preparation process or step, make soft capsule routinely.
test example:
One, pharmacological evaluation basis
Test objective:
Evaluate this Chinese prescription by pharmacological evaluation and there is the kidney invigorating soothing liver-QI, regulating qi-flowing for harmonizing stomach, hard masses softening and resolving effect, integrate the dual function of prevention and therapy.
The preparation of zoopery medication:
Get the invention described above embodiment 3 traditional Chinese medicinal composition raw materials proportioning, add 10 times of water yields and soak 1 hour, preparation process is the same, adds water to make every 1ml to carry out test containing the solution being equivalent to 3g crude drug for subsequent use, for experimental rat gastric infusion.
The foundation of animal experimental model:
Experimental animal is chosen female sd inbred rats 150 ~ 200g conventional adaptation and is raised 3 ~ 5 days, adopts rat to press 0.5mg/kg estradiol benzoate lumbar injection, every day 1 time, continuous 4 weeks, sets up cyclomastopathy pathology model.
Zoopery is divided into groups:
By kg body weight random packet, respectively organize rat body weight, second pair of breast diameter there was no significant difference after testing.Rat is equally divided into 6 groups, often organizes 10.
Blank group (N): with normal saline 0.2mL lumbar injection, every day 1 time, continuous 4 weeks, from the 5th week, only gavage distilled water 2mL/, every day 1 time, last till end in the 8th week, all the other 5 groups all by 0.5mg/kg estradiol benzoate lumbar injection, every day 1 time, modeling in continuous 4 weeks.
Model group: start for after modeling the 5th week only to gavage distilled water 2mL/, every day 1 time;
The large small dose group of experimental drug: start to gavage experimental drug 3.6g/kg, 1.8g/kg every day 1 time for after modeling the 5th week;
Western medicine group: start for after modeling the 5th week to gavage tamoxifen tablet diluent 0.5mg/kg, every day 1 time;
Chinese medicine matched group: start for after modeling the 5th week to gavage RUZENGNING PIAN agent or RUKUAIXIAO PIAN dilution agent liquid 2.5g/kg, every day 1 time.Above gastric infusion all continues to end in the 8th week.
Within 1st week, start grouping in experiment to weigh, use vernier caliper measurement rat second pair of breast diameter average 1 time weekly;
The 4th week and the 8th week in experiment starts within continuous 5 days, to carry out rat vagina cell smear (pap staining), the ovarian function situation of test experience rat.
Results of animal:
1. this Chinese prescription is on the impact of hyperplasia of mammary gland model integrality and Serum Sex Hormones:
By detecting rat body weight, breast diameter, oestrous cycle and serum sex hormone level, observe the index such as rat mammary gland, uterus, ovary tissue change, disclose with this Treated with Chinese Decoction cyclomastopathy, mastalgia, puerperal galactostasis may be the integrally-regulated effect realization by Endocrine hormone.
Normal rats is along with the increase of the time of nursing, and breast diameter is without significant change, and Mus obviously increases model group rats modeling rear udder attachment diameter compared with normal, and along with the prolongation of time, breast diameter has no and reduces, and illustrates that the breast that animal pattern increases can not disappear voluntarily; This prescription rat breast diameter obviously reduces (P < 0.01), and close to normal range.We according to rat vaginal cell in rutting period based on table, middle layer cells, a small amount of bottom cell, rutting period, rat vagina cell was based on middle and bottom layers cell, the feature of a small amount of cells of superficial layer, calculate Rats During The Estrous Cycle vaginal cell index (P+E), the ovarian function situation of test experience rat.
Experiment is by the mensuration to each group of Rats During The Estrous Cycle index (P+E), and result shows: model group comparatively blank group Rats During The Estrous Cycle index (P+E) obviously reduces (P < 0.01); This prescription has clear improvement (P < 0.01) to rat model P+E, and close to normal range; Breast increasing is rather organized rat (P+E) and is had no significant change.
Experiment is by the mensuration to each group of hormone serum level, and result shows, the rat E after estrogen modeling
2, PRL level apparently higher than normal rat, P level obviously reduces, and this prescription can make the abnormal E raised of rat model
2, PRL reduce, reach normal range, P content can be made to raise, and the excessive secretion of PRL in serum can be blocked, suppress abnormal hormone to the pessimal stimulation of mammary gland tissue.
Experiment shows, a large amount of exogenous hormoneses can cause the diacrisis of rat model serum hormone, and the present composition has the effect regulating the disorder of the hormonal readiness such as blood serum E2, P, PRL.Point out the mechanism of action of this prescription may by regulating the function of laboratory animal hypothalamic-pituitary-ovarian gonad axis thus the abnormal secretion improving Serum Sex Hormones realizes, this be one of mechanism of action of this Treated with Chinese Decoction cyclomastopathy.
By detecting rat body weight, breast diameter, oestrous cycle (see table 1-3), disclosing with the kidney invigorating soothing the liver eliminating stagnation method prescription therapeutic cyclomastopathy that is principle may be integrally-regulated effect realization by Endocrine hormone.
Table 1 respectively group cyclomastopathy rat body weight change
Note: ratio before and after the treatment of this group,
*p < 0.05,
*p < 0.01.
Table 2 is the change of group cyclomastopathy rat breast diameter respectively
Note: ratio before and after the treatment of this group, * P < 0.05, * * P < 0.01.
Table 3 respectively group cyclomastopathy Rats During The Estrous Cycle index (P+E) change
Note: ratio before and after the treatment of this group, * P < 0.05, * * P < 0.01.
2. this Chinese prescription is on the Ultrastructural impact of hyperplasia of mammary gland model mammary gland
By Electronic Speculum and immunohistochemical analysis, this Chinese drug-treated group can make mammary gland prostate lumens areas, interstitial area and nuclear area obviously decline; And endometrial mucosa projection can be improved, Interstitial cell reduces, and nuclear division reduces mutually; Make folliculus ovarii film wrinkle wall mamillary decreased number, result shows this Chinese prescription has therapeutical effect (see table 4) to cyclomastopathy and endometrial hyperplasia.
Table 4 is group mammary gland pathological morphological image com-parison and analysis respectively
Note: with normal group ratio, △ P < 0.05, △ △ P < 0.01; With model group ratio, * P < 0.05, * * P < 0.01.
3. this Chinese prescription is on the impact of hyperplasia of mammary gland model neurotransmitter and gonadal hormone
By detecting the content of neurotransmitter (dopamine, 5-hydroxy tryptamine) and Serum Sex Hormones in rat gonad target organ-mammary gland tissue, serum, find rat model estradiol (E
2), lactotropin (PRL), 5-hydroxy tryptamine obviously raise, P (progesterone), dopamine obviously reduce, and this Chinese drug-treated group can make the abnormal E raised of rat model
2, PRL reduce, reach normal range, P content obviously raised; Also there is certain regulating action to the neurotransmitter in mammary gland tissue, while rising dopamine, reduce the content of 5-hydroxy tryptamine, blocked the excessive secretion of PRL in serum, inhibit abnormal hormone to the stimulation of mammary gland tissue.Point out the mechanism of action of this Chinese prescription may by regulating the neuroendocrine function of hypothalamic-pituitary-ovarian gonad axis thus the abnormal secretion improving some neurotransmitter and Serum Sex Hormones in mammary gland tissue realizes, this may be one of mechanism of action of this Treated with Chinese Decoction cyclomastopathy (see table 5).
Table 5 mammary gland tissue, serum dopamine, 5-hydroxy tryptamine and Serum PRL change
Note: compare with matched group, * P < 0.05, * * P < 0.01; Compare with model group, △ P < 0.01.
4. this Chinese prescription is on the impact of hyperplasia of mammary gland model proliferating cell nuclear antigen and hormone receptor
Find proliferating cell nuclear antigen (PCNA) and estrogen receptor (ER) in hyperplasia of mammary gland model animal's mammary gland tissue by light microscopic and immunohistochemical staining, the positive expression of progesterone receptor (PR) obviously strengthens, this Chinese drug-treated group can make ER, PR, PCNA positive staining intensity index be down to normal range (see table 6).
Table 6 is respectively organized ER, PR, PCNA staining power index and is compared
Note: compare △ P < 0.01 with normal group, compares * P < 0.01 with model group
This test discloses with " the kidney invigorating is soothing the liver eliminating stagnation " as the Chinese traditional compound medicine of method for the treatment of can regulate hormone serum level, reduce mammary gland tissue to the sensitivity of Estrogen and progestin, stop the overexpression of proliferating cell nuclear antigen, suppress further developing of cyclomastopathy, can play the dual function for the treatment of and prevention, theoretical basis has been established in the canceration for Chinese medicine preventing mammary gland hyperplasia.
Beneficial effect of the present invention
1. create cyclomastopathy " the kidney invigorating is soothing the liver eliminating stagnation " method
Investigation finds, in Patients of Mammary Gland Hyperplasia menophania early, menopause evening, do not give birth to, non-suckling, artificial abortion, happiness higher fatty acid factor proportion be high.More than 80% patient is because of psychentonia aggravation.Think that the factors such as the generation of primary disease and feelings will, diet, environment, heredity, relevant disease are relevant, Liver and kidney thin and weak with the menses of Chinese medicine loses supports, and the liver failing to maintain the normal flow of QI matches.The rule evolution of a blood stasis is coagulated in the change of disease according to the stagnation of QI one expectorant.Suffer from a deficiency of the kidney then through the overall process that the course of disease develops.Sum up the pathogenic characteristic of this disease with stagnation of liver-QI kidney asthenia as the principal aspect, the stagnation of QI, expectorant are solidifying, blood stasis is mark, found the therapeutic rules of " the kidney invigorating is soothing the liver eliminating stagnation ".
2. improve cyclomastopathy syndrome to objectify research
The performance of the B ultrasonic of Patients of Mammary Gland Hyperplasia and menstruation follicular phase, luteal phase, the onset of ovulation, the estrogen and progestogen level of premenstrua and the dependency of tcm syndrome are inquired into, find that these indexs and syndrome have certain dependency, sum up cyclomastopathy with kidney asthenia as the principal aspect, the stagnation of QI can be had again concurrently, expectorant coagulates, blood stasis three type, lobulus simplex Accretive Type, cystic cyclomastopathy type, the gland type cyclomastopathy type of corresponding B ultrasonic typing respectively; The change of menstrual cycle Estrogen and progestin level is closely related with the differentiation of symptoms and signs for classification of syndrome of cyclomastopathy, and the research that objectifies of the tcm syndrome for cyclomastopathy provides foundation.
3. set up cyclomastopathy Quantitative Diagnosis of TCM Syndrome standard and therapeutic efficacy assessment
Utilize the design of system, establish corresponding Quantitative Diagnosis of TCM Syndrome standard, cyclomastopathy Quantitative Diagnosis of TCM Syndrome table, cyclomastopathy case history observation table and objective scale point system are drafted, complete the transformation of Chinese traditional medical diagnose data by grade distinguishing vectorization standard, perfect corresponding syndrome quantized diagnosis standard and therapeutic efficacy assessment; Compare according to the Changing Pattern of Serum Sex Hormones and symptom integral value, for the improvement of the local sign and General Symptoms of passing judgment on cyclomastopathy, for the science demonstration of Chinese medicine primary disease provides thinking.
Claims (9)
1. treat cyclomastopathy, mastalgia, puerperal galactostasis and/or the Chinese medicine composition of relevant disease, it is characterized in that being made up, based on parts by weight of following crude drug, Cornu Cervi Degelatinatum 9-15 part, Ramulus Cinnamomi 9-15 part, Radix Bupleuri 9-15 part, Fructus Trichosanthis 8-12 part, Radix Angelicae Sinensis 8-12 part, Rhizoma Chuanxiong 8-12 part, Fructus Liquidambaris 5-9 part, Concha Ostreae 9-15 part, Flos Albiziae 5-9 part, Fructus Hordei Germinatus 5-9 part.
2. Chinese medicine composition according to claim 1, is characterized in that being made up, based on parts by weight of following crude drug, Cornu Cervi Degelatinatum 10-13 part, Ramulus Cinnamomi 10-13 part, Radix Bupleuri 10-13 part, Fructus Trichosanthis 9-11 part, Radix Angelicae Sinensis 9-11 part, Rhizoma Chuanxiong 9-11 part, Fructus Liquidambaris 6-8 part, Concha Ostreae 10-14 part, Flos Albiziae 6-8 part, Fructus Hordei Germinatus 6-8 part.
3. a preparation method for Chinese medicine composition according to claim 1, is characterized in that getting the crude drug by above-mentioned weight proportion, by pharmaceutics conventional method, adds customary adjuvant, is prepared into various clinical acceptable dosage form.
4. preparation method according to claim 3, is characterized in that described dosage form is selected from peroral dosage form or exterior-applied formulation.
5. preparation method according to claim 3, is characterized in that described dosage form is selected from the dosage form of topical.
6. preparation method according to claim 3, is characterized in that described dosage form is selected from tablet, capsule, patch, gel, injection, pill, granule, suspensoid.
7. preparation method according to claim 3, is characterized in that described dosage form is selected from soft capsule, drop pill.
8. preparation method according to claim 3, is characterized in that described dosage form is selected from oral liquid.
9. one kind according to claim 1 Chinese medicine composition prepare cyclomastopathy, mastalgia, puerperal galactostasis medicine in application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310420009.3A CN103446500B (en) | 2013-09-16 | 2013-09-16 | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310420009.3A CN103446500B (en) | 2013-09-16 | 2013-09-16 | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103446500A CN103446500A (en) | 2013-12-18 |
| CN103446500B true CN103446500B (en) | 2015-03-11 |
Family
ID=49729612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310420009.3A Expired - Fee Related CN103446500B (en) | 2013-09-16 | 2013-09-16 | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103446500B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105148126B (en) * | 2015-09-22 | 2018-11-27 | 广州奇绩医药科技有限公司 | A kind of health food with improvement proliferation of mammary gland pain function |
| CN105194394A (en) * | 2015-10-13 | 2015-12-30 | 臧海阳 | Traditional Chinese medicine composition for treating breast nodules caused by kidney deficiency and stagnation of liver qi |
| CN105381122A (en) * | 2015-11-30 | 2016-03-09 | 潘素荣 | Hard lump-resolving preparation for treating hyperplasia of mammary glands and preparation method for hard lump-resolving preparation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772142A (en) * | 2005-10-17 | 2006-05-17 | 李亚萍 | Chinese herbal medicine decoction for treating liver energy stagnation and phlegm accumulation type mastoproliferation and its prepn |
| CN1958006A (en) * | 2006-11-15 | 2007-05-09 | 王信锁 | Preparation of Chinese traditional medicine for healthy chest and plumpy breasts |
| CN101011491A (en) * | 2007-01-24 | 2007-08-08 | 辽宁好护士药业（集团）有限责任公司 | Granule for expelling obstruction of galactophore and its preparation method |
| CN101716299A (en) * | 2009-11-16 | 2010-06-02 | 崔静 | Traditional Chinese medicine composition for treating hyperplasia of mammary glands |
-
2013
- 2013-09-16 CN CN201310420009.3A patent/CN103446500B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772142A (en) * | 2005-10-17 | 2006-05-17 | 李亚萍 | Chinese herbal medicine decoction for treating liver energy stagnation and phlegm accumulation type mastoproliferation and its prepn |
| CN1958006A (en) * | 2006-11-15 | 2007-05-09 | 王信锁 | Preparation of Chinese traditional medicine for healthy chest and plumpy breasts |
| CN101011491A (en) * | 2007-01-24 | 2007-08-08 | 辽宁好护士药业（集团）有限责任公司 | Granule for expelling obstruction of galactophore and its preparation method |
| CN101716299A (en) * | 2009-11-16 | 2010-06-02 | 崔静 | Traditional Chinese medicine composition for treating hyperplasia of mammary glands |
Non-Patent Citations (1)
| Title |
|---|
| 乔迪.乳络通汤剂配合按摩治疗急性乳腺炎的疗效观察,.《中国中西医结合急救杂志》.1996,第3卷(第3期),99-100. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103446500A (en) | 2013-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526634B (en) | Traditional Chinese medicine preparation for curing hyperplasia of mammary glands | |
| CN104840904A (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands | |
| CN101632820B (en) | Intestinal obstruction removal pill | |
| CN104826016B (en) | A kind of pharmaceutical composition and its preparation method and application for treating the proliferation of mammary gland | |
| CN102284050B (en) | Chinese medicine composition for treating infertility caused by cold uterus | |
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| CN103536742B (en) | A kind ofly treat pharmaceutical composition of chronic enterogastritis disease and preparation method thereof | |
| CN103446500B (en) | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction | |
| CN104740536A (en) | Pharmaceutical composition for treating endometriosis (EMT) and adenomyosis (AM) and preparation method and use thereof | |
| CN102178828A (en) | Medicament for treating proliferation of mammary gland and preparation method thereof | |
| CN101168003A (en) | Traditional Chinese medicinal composition for preparing medicine for preventing and treating gynopathy | |
| CN105797046A (en) | Traditional Chinese medicine composition for uterine fibroid treatment and postoperative nursing | |
| CN105943758B (en) | A kind of Chinese medicine composition that treating infertility and its application | |
| CN103736003A (en) | Medicament for treating mammary hyperplasia | |
| CN103212030B (en) | Traditional Chinese medicine for treating liver depression type hyperplasia of mammary glands and preparation method thereof | |
| CN103285338A (en) | Externally applied traditional Chinese medicament for treating breast hyperplasia disease | |
| CN103768478A (en) | Traditional Chinese medicine composition for treating prostatitis and preparation method and application thereof | |
| CN101979082A (en) | Medicament for treating cyclomastopathy and preparation method and application thereof | |
| CN104474456A (en) | Traditional Chinese medicinal pill for treating hysteromyoma | |
| CN103520354A (en) | Traditional Chinese medicine for treatment of blood-insufficiency type mammary gland hyperplasia and preparation method thereof | |
| CN103520638B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof | |
| CN102861185A (en) | Application of traditional Chinese medicine composition in preparing drugs for treating secondary dysmenorrhea | |
| CN105833209A (en) | Traditional Chinese medicine composition for treating endometriosis uterina | |
| CN105998290A (en) | Traditional Chinese medicine composition for treating early woman amenorrhea and preparing method thereof | |
| CN104435734A (en) | Traditional Chinese medicine preparation for nursing uterine leiomyoma and preparation method of traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Ma Jinge Document name: Notification of Patent Invention Entering into Substantive Examination Stage |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150311 |